Base metrics
- Operating margin
- 31.1%
- Interest coverage
- 20.8x
- Return on equity (ROE)
- 23.2%
BIOBIJOU financial statements
바이오비쥬KRX:489460 · KOSDAQ₩11,780+0.00%
2026-10-08 closeBIOBIJOU's 2025 annual results accompany close-price data dated 2026-10-08. 2025 revenue was KRW 28.49B. 2025 operating profit was KRW 4.23B.
Reported results
Financial safety
Reference indicatorAs of 2024Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 11.57
Distress
Grey
Safe
- Altman Z''
- 11.57
- Beneish M-Score
- —
- Sloan accrual
- 17.54%
Statistical flag unavailable
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
2/9Weak
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score2/9
Profitability
- Positive ROAPass
- Positive OCFPass
- Improving ΔROANot passed
- Accruals (OCF > net income)Not passed
Leverage & liquidity
- Lower debtNot passed
- Higher current ratioNot passed
- No new sharesNot passed
Efficiency
- Higher gross marginNot passed
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Operating margin −5pp
TolerableInterest coverageBase 20.8x adverse case 17.4x
Return on equity (ROE)Base 23.2% adverse case 23.6%
Revenue −15%
TolerableInterest coverageBase 20.8x adverse case 17.7x
Return on equity (ROE)Base 23.2% adverse case 23.9%
Interest rate +2pp
TolerableInterest coverageBase 20.8x adverse case 15.9x
Return on equity (ROE)Base 23.2% adverse case 27.9%
Interest coverage limit
Current margin 29.6ppInterest coverage limit at an operating margin of 1.5%
Interest expense coverage threshold
Quantus Signal · live data · not investment advice · Privacy Policy